Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of MTX-101 in Healthy Adults and Type 1 Diabetes Patients
NCT06324604Phase 1Recruiting
- Sponsor
- Mozart Therapeutics
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MTX-101 in type 1 diabetes mellitus (T1D) (8 cohorts), sponsored by Mozart Therapeutics. Primary endpoint: Safety and Tolerability at 11 weeks. Started Jun 2024; status: recruiting.
02
Drugs
MTX-101
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06324604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324604.